Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial

Marwick, TH; Dewar, E; Nolan, M; Shirazi, M; Dias, P; Wright, L; Fitzgerald, B; Kearney, L; Srivastava, P; Atherton, J; Negishi, K; Sverdlov, AL; Wahi, S; Otton, J; Selvanayagam, J; Thomas, L; Thavendiranathan, P; SUCCOUR-MRI Investigators

Author(s): Marwick, TH; Dewar, E; Nolan, M; Shirazi, M; Dias, P; Wright, L; Fitzgerald, B; Kearney, L; Srivastava, P; Atherton, J; Negishi, K; Sverdlov, AL; Wahi, S; Otton, J; Selvanayagam, J; Thomas, L; Thavendiranathan, P; SUCCOUR-MRI Investigators;
Details: Publication Year 2024-11-07,Volume 45,Issue #41,Page 4414-4424
Journal Title: European Heart Journal
Publication Type: Research article
Abstract: BACKGROUND AND AIMS: The detection of cancer therapy-related cardiac dysfunction (CTRCD) by reduction of left ventricular ejection fraction (LVEF) during chemotherapy usually triggers the initiation of cardioprotective therapy. This study addressed whether the same approach should be applied to patients with worsening of global longitudinal strain (GLS) without attaining thresholds of LVEF. METHODS: Strain surveillance during chemotherapy for improving cardiovascular outcomes (SUCCOUR-MRI) was a prospective multicentre randomized controlled trial involving 14 sites. Of 355 patients receiving anthracyclines with normal baseline LVEF, 333 patients (age 59 ± 13 years, 79% women) with at least one other CTRCD risk factor, able to undergo magnetic resonance imaging (MRI), GLS, and three-dimensional echocardiography were tracked over 12 months. A total of 105 patients (age 59 ± 13 years, 75% women, 69% breast cancer) developing GLS-CTRCD (>12% relative reduction of GLS without a change in LVEF) were randomized to cardioprotection with neurohormonal antagonists vs. usual care. The primary endpoint was 12-month change in MRI-LVEF; the secondary endpoint was MRI-LVEF-defined CTRCD. RESULTS: During follow-up, two patients died, and two developed heart failure. Most patients were randomized at 3 months (62%). Median doses of angiotensin inhibition/blockade and beta-blockade were 75% and 50% of respective targets; 21 (43%) had side-effects attributed to cardioprotection. Due to a smaller LVEF change from baseline with cardioprotection than usual care (-2.5 ± 5.4% vs. -5.6 ± 5.9%, P = .009), follow-up LVEF was higher after cardioprotection (59 ± 5% vs. 55 ± 6%, P < .0001). After adjustment for baseline LVEF, the mean (95% confidence interval) difference in the change in LVEF between the two groups was -3.6% (-1.8% to -5.5%, P < .001). After cardioprotection, 1/49 patients developed 12-month LVEF-CTRCD, compared to 6/56 in usual care (P = .075). Global longitudinal strain improved at 3 months post-randomization in the cardioprotection group, with little change with usual care. CONCLUSIONS: In patients with isolated GLS reduction after anthracyclines, cardioprotection is associated with better preservation of 12-month MRI-LVEF compared with usual care.
Publisher: Oxford University Press
Keywords: Humans; Female; Middle Aged; Male; Prospective Studies; *Stroke Volume/drug effects/physiology; Aged; Anthracyclines/adverse effects; Antineoplastic Agents/adverse effects; Magnetic Resonance Imaging/methods; Ventricular Dysfunction, Left/diagnostic imaging/chemically induced; Neoplasms/drug therapy; Cancer therapy-related cardiac dysfunction; Global longitudinal strain; Left ventricular ejection fraction
Department(s): Internal Medicine
Publisher's Version: https://doi.org/10.1093/eurheartj/ehae574
Open Access at Publisher's Site: https://doi.org/10.1093/eurheartj/ehae574
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-12-17 06:25:45

Last Modified: 2024-12-17 06:25:56